Invion (IVX.AX) Stock Price
Invion Price
Over the last 16 years Invion grew revenue by 6.5% annually, reaching 385,319.00 AUD. For Invion, the net margin of -1,461.9% is down versus -63.6% a few years ago.
Invion stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Invion business model & stock analysis
Frequently asked questions about Invion
Invion Ltd is a biotechnology company focused on the development of therapies for respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company's business model is centered around research and development of innovative treatments using their proprietary Photosoft™ platform technology. This platform enables the formulation of targeted therapies that can be delivered via inhalation, providing potential benefits for patients in terms of improved efficacy and reduced side effects. Through strategic partnerships and collaborations, Invion aims to commercialize its products globally and make a significant impact on the treatment of respiratory conditions.
Invion Ltd is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Invion Ltd in the market are companies such as AstraZeneca, GlaxoSmithKline, Novartis, and Pfizer. These pharmaceutical giants compete with Invion Ltd in the development and commercialization of various drugs and therapies. While Invion Ltd focuses on the research and development of novel treatments in areas such as respiratory diseases, inflammatory diseases, and autoimmune conditions, its competitors also have diverse portfolios and significant market presence. Therefore, Invion Ltd faces competition from well-established players within the pharmaceutical industry.
Invion Ltd is a pharmaceutical company based in Australia. Established in 2000, Invion specializes in the development and commercialization of treatments for chronic inflammatory diseases. With a focus on respiratory conditions, the company aims to improve the lives of patients through innovative therapies. Invion's history is marked by a dedication to scientific research and strategic collaborations with industry partners. As a leading player in the field, Invion has a proven track record of developing novel solutions for unmet medical needs. With a commitment to advancing healthcare, Invion Ltd continues to make significant contributions to the pharmaceutical industry.
Invion Ltd has achieved several significant milestones. The company successfully completed a merger with CBio Limited, expanding its portfolio of immunotherapy assets. Invion also received approval for clinical trials of INV103, a potential treatment for asthma. Furthermore, the company obtained positive results from preclinical studies of INV102, an investigational therapy for chronic inflammatory diseases. Invion's partnership with Hudson Institute of Medical Research and Monash University strengthens its research capabilities. The company continues to advance its drug development programs and explore market opportunities. Invion Ltd's achievements illustrate its commitment to innovation and improving patients' lives.
Invion Ltd is primarily present in Australia and the United States.
Invion Ltd represents values of innovation, sustainability, and excellence in the pharmaceutical industry. The company is committed to developing and commercializing cutting-edge therapies to address unmet medical needs. Invion Ltd follows a patient-centric approach and strives to improve health outcomes globally. With a focus on research and development, Invion Ltd embraces collaboration with partners to bring novel treatments to market. The company's corporate philosophy entails a commitment to transparency, ethical conduct, and delivering value to shareholders. Invion Ltd's comprehensive understanding of medical science and dedication to improving lives align with its core values and guiding principles.
Converted at the current exchange rate, the Invion share trades at 0.02 EUR (0.03 AUD).
The Invion share (IVX.AX) is listed on 3 stock exchanges, including: ASX (IVX.AX), Frankfurt (7C8.F).
Invion Ltd is a company that operates in the biotechnology industry and focuses on the development of new therapies for various diseases. The company has several business areas, including drug development, drug manufacturing, and collaboration with other companies and research institutions. One of Invion's focuses is the discovery and development of new drugs for the treatment of serious diseases such as cancer, chronic respiratory diseases, and inflammatory diseases. The company uses innovative technologies and advanced research methods to identify and optimize potential active substances. Another area of Invion is the manufacturing and marketing of drugs that are already on the market. The company focuses on the production of high-quality generic drugs that are offered at an affordable price. Invion works closely with authorities and regulatory bodies to ensure that all products comply with strict regulations. Furthermore, Invion is committed to collaborating with other companies and research institutions to jointly develop new technologies and therapies. The company works closely with leading experts to find innovative therapeutic approaches and implement them quickly in practice. Invion's products include medications for the treatment of asthma and chronic bronchitis, as well as various cancer therapies and antiviral drugs. In addition, the company is involved in the development of vaccines and other immunotherapies that can be used to treat severe infectious diseases. To achieve its business goals, Invion relies on strategic business planning and a clear focus on innovative research and development. The company has a strong financial foundation and an experienced management team that guides the company's fortunes. Overall, Invion Ltd is a company specialized in the advancements in biotechnology and focuses on the development of new and innovative therapies. The company follows a clear strategy based on research and development and collaborations with other companies and research institutions. Through its coverage of various sectors and clear focus on innovation, the company will be successful.
The revenue of Invion is 385,319.00 AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Invion is -5.63 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Invion is currently -0.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Invion stock.
The price-to-sales ratio (P/S) of Invion is currently 8.74. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Invion stock.
The Eulerpool Quality Score for Invion is 3/10.
The ISIN of Invion is AU000000IVX4. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Invion is A1J3RR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Invion is IVX.AX. The ticker symbol is used to trade Invion shares on the stock exchange.
Invion stock
Invion Peer Group
Invion Ticker
Invion FIGI
All fundamentals and in-depth analysis of Invion
Our stock analysis for Invion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Invion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.